Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 546,520 |
|
|||||
| News | - | ||||||
| Day High | 1.35 | Low High |
|||||
| Day Low | 1.28 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Panacea Acquisition Corp | NUVB | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.04 | 3.1% | 1.33 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.30 | 1.28 | 1.35 | 1.33 | 1.29 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,662 | 546,520 | US$ 1.32 | US$ 721,603 | - | 0.95 - 2.545 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:00:00 | 69,803 | US$ 1.33 | USD |
Panacea Acquisition Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 291.2M | 218.94M | - | 0 | -104.2M | -0.48 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Panacea Acquisition News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/27/2023 | 15:09 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 11/27/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/13/2023 | 15:11 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/13/2023 | 15:05 | Business Wire | Nuvation Bio Announces Departure of Chief Financial Officer |
| 11/02/2023 | 15:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/02/2023 | 15:21 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/02/2023 | 15:10 | Business Wire | Nuvation Bio Reports Third Quarter 2023 Financial Results.. |
| 8/03/2023 | 16:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/03/2023 | 15:17 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/03/2023 | 15:10 | Business Wire | Nuvation Bio Reports Second Quarter 2023 Financial Results.. |
| 6/01/2023 | 15:05 | Business Wire | Nuvation Bio Announces Formation of Oncology-Focused.. |
| 5/04/2023 | 15:05 | Business Wire | Nuvation Bio Reports First Quarter 2023 Financial Results.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NUVB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.27 | 1.38 | 1.22 | 1.32 | 846,803 | 0.06 | 4.72% |
| 1 Month | 1.24 | 1.41 | 1.21 | 1.29 | 1,114,799 | 0.09 | 7.26% |
| 3 Months | 1.38 | 1.45 | 0.95 | 1.20 | 1,540,314 | -0.05 | -3.62% |
| 6 Months | 1.78 | 2.13 | 0.95 | 1.34 | 966,397 | -0.45 | -25.28% |
| 1 Year | 1.98 | 2.545 | 0.95 | 1.54 | 798,441 | -0.65 | -32.83% |
| 3 Years | 10.00 | 15.23 | 0.95 | 5.26 | 850,376 | -8.67 | -86.7% |
| 5 Years | 10.00 | 15.23 | 0.95 | 5.26 | 850,376 | -8.67 | -86.7% |
Panacea Acquisition Description
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. |
